Laboratory Medicine ›› 2017, Vol. 32 ›› Issue (5): 347-352.DOI: 10.3969/j.issn.1673-8640.2017.05.001
• Orginal Article • Next Articles
Received:2017-05-08
Online:2017-05-20
Published:2017-06-06
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2017.05.001
| [1] | 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J]. 临床肿瘤学杂志,2011,16(10):929-946. |
| [2] | KOKUDO N,HASEGAWA K,AKAHANE M,et al.Evidence-based clinical practice Guidelines for hepatocellular carcinoma:the Japan Society of Hepatology 2013 update (3rd JSH-HCC guidelines)[J]. Hepatol Res,2015,45(2):123-127. |
| [3] | HOOFNAGLE J H,DOO E,LIANG T J,et al.Management of hepatitis B: summary of a clinical research workshop[J]. Hepatology,2007,45(4):1056-1075. |
| [4] | GANEM D,PRINCE A M.Hepatitis B virus infection-natural history and clinical consequences[J]. N Engl J Med,2004,350(11):1118-1129. |
| [5] | THEIN H H,YI Q,DORE G J,et al.Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection:a meta-analysis and meta-regression[J]. Hepatology,2008,48(2):418-431. |
| [6] | EL-SERAG H B,RUDOLPH K L. Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J]. Gastroenterology,2007,132(7):2557-2576. |
| [7] | SATO Y,NAKATA K,KATO Y,et al.Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein[J]. N Engl J Med,1993,328(25):1802-1806. |
| [8] | HU B,TIAN X,SUN J,et al.Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma:a meta-analysis[J]. Int J Mol Sci,2013,14(12):23559-23580. |
| [9] | HADZIYANNIS E,SIALEVRIS K,GEORGIOU A,et al.Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels[J]. Oncol Rep,2013,29(2):835-839. |
| [10] | SONG P,FENG X,ZHANG K,et al.Perspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker:facilitating early detection of hepatocellular carcinoma in China[J]. Hepatobiliary Surg Nutr,2013,2(4):227-231. |
| [11] | KUMADA T,TOYODA H,TADA T,et al.High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma[J]. J Gastroenterol,2014,49(3):555-563. |
| [12] | TATEISHI R,YOSHIDA H,MATSUYAMA Y,et al.Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review[J]. Hepatol Int,2008,2(1):17-30. |
| [13] | TOYODA H,KUMADA T,TADA T.Highly sensitive Lens culinaris agglutinin-reactive α-fetoprotein: a new tool for the management of hepatocellular carcinoma[J]. Oncology,2011,81(Suppl 1):61-65. |
| [14] | THOMAS M B,JAFFE D,CHOTI M M,et al.Hepatocellular carcinoma:consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting[J]. J Clin Oncol,2010,28(25):3994-4005. |
| [15] | HANAOKA T,SATO S,THBITA H,et al.Clinical significance of the highly sensitive fucosylated fraction of α-fetoprotein in patients with chronic liver disease[J]. J Gastroenterol Hepatol,2011,26(4):739-744. |
| [16] | VOLK M L,HERNANDEZ J C,SU G L,et al.Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP,DCP,and AFP-L3[J]. Cancer Biomark,2007,3(2):79-87. |
| [17] | MARRERO J A,FENG Z,WANG Y,et al.Alpha-fetoprotein,des-gamma carboxyprothrombin,and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma[J]. Gastroenterology,2009,137(1):110-118. |
| [18] | 徐万菊,韩玉刚,张芊,等. 甲胎蛋白异质体与高尔基体蛋白73在甲胎蛋白低浓度肝细胞癌诊断中的意义[J]. 中华检验医学杂志,2012,35(2):174-176. |
| [19] | 胡敏华,陈燕,梁亚嘉,等. 新微量离心柱法测定甲胎蛋白异质体对原发性肝癌诊断的价值(附297例分析)[J]. 福建医药杂志,2009,31(4):95-96. |
| [20] | 徐恩君,陈秋莉,李涛,等. 血清AFP、AFP-L3联合检测在原发性肝癌中的诊断价值[J]. 安徽医科大学学报,2016,51(7):1066-1070. |
| [21] | 季君,顾星,高致远,等. 凝集素捕获微量离心柱法检测甲胎蛋白异质体在原发性肝癌中的应用评价[J]. 检验医学,2011,26(4):256-259. |
| [22] | OKUDA H,SAITO A,SHIRATORI K,et al.Clinicopathologic features of patients with primary malignant hepatic tumors seropositive for alpha-fetoprotein-L3 alone in comparison with other patients seropositive for alpha-fetoprotein-L3[J]. J Gastroenterol Hepatol,2005,20(5):759-764. |
| [23] | TADA T,KUMADA T,TOYODA H,et al.Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma[J]. Liver Int,2005,25(4):848-853. |
| [24] | OKUDA H,NAKANISHI T,TAKATSU K,et al.Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone[J]. J Gastroenterol Hepatol,2002,17(7):772-778. |
| [25] | MATSUDA M,ASAKAWA M,AMEMJYA H,et al.Lens culinaris agglutinin-reactive fraction of AFP is a useful prognostic biomarker for survival after repeat hepatic resection for HCC[J]. J Gastroenterol Hepatol,2011,26(4):731-738. |
| [26] | SAITO Y,SHIMADA M,UTSUNOMIYA T,et al.Prediction of recurrence of hepatocellular carcinoma after curative hepatectomy using preoperative Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein[J]. Hepatol Res,2012,42(9):887-894. |
| [27] | KIRIYAMA S,UCHIYAMA K,UENO M,et al.Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival[J]. Ann Surg,2011,254(6):984-991. |
| [28] | NAKAGAWA S,BEPPU T,OKABE H,et al.Triple positive tumor markers predict recurrence and survival in early stage hepatocellular carcinoma[J]. Hepatol Res,2014,44(9):964-974. |
| [29] | KOBAYASHI M,HOSAKA T,IKEDA K,et al.Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively[J].Hepatol Res,2011,41(11):1036-1045. |
| [30] | WANG F S,FAN J G,ZHANG Z,et al.The global burden of liver disease:the major impact of China[J]. Hepatology,2014,60(6):2099-2108. |
| [31] | FATTOVICH G,STROFFOLINI T,ZAGNI I,et al.Hepatocellular carcinoma in cirrhosis:incidence and risk factors[J]. Gastroenterology,2004,127(5 Suppl 1):S35-S50. |
| [32] | OKUDA H,SHIRATORI K,YAMAMOTO M,et al.Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma[J]. J Gastroenterol Hepatol,2006,21(5):869-873. |
| [33] | CHOI J,PARK Y,KIM J H,et al.Evaluation of revisited fucosylated alpha-fetoprotein (AFP-L3) with an autoanalyzer μTAS in a clinical laboratory[J]. Clin Chim Acta,2012,413(1-2):170-174. |
| [34] | KUROSAWA T,WATANABE M.Development of on-chip fully automated immunoassay system "μTASWako i30" to measure the changes in glycosylation profiles of alpha-fetoprotein in patients with hepatocellular carcinoma[J]. Proteomics,2016,16(24):3056-3061. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
